MK2140-011

About this trial

This clinical trial is testing two different drug combinations to treat a type of blood cancer called DLBCL, specifically the GCB subtype. It compares a newer medicine called zilovertamab vedotin with an existing one called polatuzumab vedotin. Both are given alongside standard chemotherapy drugs. The goal is to see which combination works better at shrinking the cancer, keeping it from coming back, and causing fewer side effects. People in the trial have not yet received treatment for their DLBCL. By studying these options, researchers hope to improve outcomes and offer better choices for patients with this form of lymphoma.

Patient Profile

This trial is for adults who have been diagnosed with a form of cancer known as germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL), and have never been treated for this before.

Where’s this trial being run?

St Vincents University Hospital, University Hospital Limerick, and Mater Misericordiae University Hospital

Can I join this study / trial?

The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.

It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	MK2140-011
Number:	25-26
Full Title:	A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/​waveLINE-011)

Principal Investigator:	N/A
Type:
Sponsor:	Merck Sharp & Dohme LLC
Recruitment Started:	Global: April 2025 Ireland:

Global Recruitment Target:	594
Ireland Recruitment Target:	12